

Pavel Olegovich Bochkov

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1703668/publications.pdf>

Version: 2024-02-01

21
papers

116
citations

1651377

6
h-index

1526636

10
g-index

22
all docs

22
docs citations

22
times ranked

119
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparative polymyxin B pharmacokinetics in patients receiving extracorporeal membrane oxygenation. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 1379-1384.	1.3	8
2	Determination of a novel anticonvulsant drug GIZh-290 in rat plasma by liquid chromatography-tandem mass spectrometry. <i>Pharmacokinetics and Pharmacodynamics</i> , 2022, , 3-10.	0.1	0
3	Influence of Clinically Significant Genes on Antiplatelet Effect of Clopidogrel and Clinical Outcomes in Patients with Acute Coronary Syndrome and Atrial Fibrillation. <i>Pharmacology</i> , 2022, 107, 216-226.	0.9	3
4	Absolute bioavailability of a substance with cardioprotective activity (ALM-802) in rats. <i>Pharmacokinetics and Pharmacodynamics</i> , 2022, , 31-35.	0.1	1
5	MicroRNAs as novel biomarkers for rivaroxaban therapeutic drug monitoring. <i>Drug Metabolism and Personalized Therapy</i> , 2022, 37, 41-46.	0.3	2
6	Pharmacokinetics of a novel anticonvulsant drug GIZh-290 in rat plasma by liquid chromatography-tandem mass spectrometry. <i>Pharmacokinetics and Pharmacodynamics</i> , 2022, , 3-10.	0.1	0
7	Effect of Clinically Significant Genes on Antiplatelet Effect of Clopidogrel and Clinical Outcomes in Patients with Acute Coronary Syndrome and Atrial Fibrillation. <i>Pharmacology</i> , 2022, 107, 216-226.	0.9	3
8	Absolute bioavailability of a substance with cardioprotective activity (ALM-802) in rats. <i>Pharmacokinetics and Pharmacodynamics</i> , 2022, , 31-35.	0.1	1
9	MicroRNAs as novel biomarkers for rivaroxaban therapeutic drug monitoring. <i>Drug Metabolism and Personalized Therapy</i> , 2022, 37, 41-46.	0.3	2
10	Pharmacokinetic relationships in psychotropic drugs effects. <i>Pharmacokinetics and Pharmacodynamics</i> , 2021, , 3-8.	0.1	0
11	MicroRNAs as novel biomarkers for rivaroxaban therapeutic drug monitoring. <i>Drug Metabolism and Personalized Therapy</i> , 2021, .	0.3	0
12	Effect of CES1 and ABCB1 genotypes on the pharmacokinetics and clinical outcomes of dabigatran etexilate in patients with atrial fibrillation and chronic kidney disease. <i>Drug Metabolism and Personalized Therapy</i> , 2020, 35, .	0.3	15
13	Factors Affecting Trough Plasma Dabigatran Concentrations in Patients with Atrial Fibrillation and Chronic Kidney Disease. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2020, 27, 151-156.	1.0	8
14	CYP2C19*17 May Increase the Risk of Death Among Patients with an Acute Coronary Syndrome and Non-Valvular Atrial Fibrillation Who Receive Clopidogrel and Rivaroxaban. <i>Pharmacogenomics and Personalized Medicine</i> , 2020, Volume 13, 29-37.	0.4	10
15	Drug-drug interaction of rivaroxaban and calcium channel blockers in patients aged 80 years and older with nonvalvular atrial fibrillation. <i>Drug Metabolism and Personalized Therapy</i> , 2020, .	0.3	5
16	The pharmacokinetics of the injectable dosage form of GK-2 in rabbits. <i>Pharmacokinetics and Pharmacodynamics</i> , 2020, , 17-21.	0.1	0
17	Safety of dabigatran in patients with atrial fibrillation and chronic kidney disease: pharmacokinetic and pharmacogenetic aspects. <i>Meditsinskiy Sovet</i> , 2020, , 65-73.	0.1	0
18	HPLC-MS method development and validation for simultaneous quantitation of GZK-111 and CPG compounds in rat plasma. <i>Pharmacokinetics and Pharmacodynamics</i> , 2020, , 28-36.	0.1	1

#	ARTICLE	IF	CITATIONS
19	Drug–drug interaction of rivaroxaban and calcium channel blockers in patients aged 80 years and older with nonvalvular atrial fibrillation. <i>Drug Metabolism and Drug Interactions</i> , 2020, 35, .	0.3	4
20	Effect of CYP3A4, CYP3A5, ABCB1 Gene Polymorphisms on Rivaroxaban Pharmacokinetics in Patients Undergoing Total Hip and Knee Replacement Surgery. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2019, 26, 413-420.	1.0	25
21	The impact of ABCB1 (rs1045642 and rs4148738) and CES1 (rs2244613) gene polymorphisms on dabigatran equilibrium peak concentration in patients after total knee arthroplasty. <i>Pharmacogenomics and Personalized Medicine</i> , 2018, Volume 11, 127-137.	0.4	34